Previous 10 | Next 10 |
A group of global institutions led by the International Monetary Fund (IMF) has proposed $15 billion in grants this year and $10 billion annually thereafter as part of a global strategy to address the long-term risks of COVID-19. The IMF, in partnership with the Coalition for Epidemic Prepare...
Sinovac Biotech (NASDAQ:SVA) said a study in Hong Kong suggested that three shots of its COVID-19 vaccine CoronaVac offered ~98% protection against death or severe illness in people over 60 years of age. The study, however also showed that for people 60 and older, two Sinovac doses were ...
Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, announced today its unaudited financial results for the six months ended June 30, 2021. First Half of 2021 Financial Summary ...
Two doses and a booster of Sinovac's (NASDAQ:SVA) COVID-19 vaccine, CoronaVac didn’t produce sufficient levels of neutralizing antibodies to protect against the Omicron variant, Reuters reports. The analysis revealed Pfizer-BioNTech vaccine was more effective, as a third dose administe...
Israel is set to become the first country in the world to administer a fourth COVID-19 vaccine, which would give "greater protection in the face of Omicron." The first eligible group to receive the vaccine will be people age 60 and older, as well as the immunocompromised and medical personnel...
Two key legal developments could soon pave the way for a resumption of trading in shares of Nasdaq-listed Sinovac, ending a nearly three-year suspension. Company’s revenue may have risen 80-fold or more since the suspension thanks to sales of its globally accepted CoronaVac Cov...
SINOVAC Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, announced the Company’s subsidiary SINOVAC Biotech Co., Ltd (“SINOVAC Beijing”) settled the litigation with Mr. Ai...
SINOVAC Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, announced new preliminary data on its inactivated COVID-19 vaccine CoronaVac®. The results from statistics analysis under blind st...
Ocugen (OCGN +11.2%) has extended gains to reach the highest level since May ahead of a key meeting of an advisory panel of the World Health Organization (WHO) to decide on the emergency use listing for the COVID-19 vaccine it has partnered with Bharat Biotech. Last week, the WHO’...
France's Sanofi will acquire Kadmon Holdings of New York City in a $1.9 billion deal. Frontage Shanghai, a division of US-China CRO Frontage Holdings, acquired a 70% stake in Wuhan Heyan Biomedical Technology, a discovery CRO. Sinovac Biotech reported that a third dose of its inac...
News, Short Squeeze, Breakout and More Instantly...
--News Direct-- LONDON, Ontario; BOSTON, Massachusetts – TheNewswire – May 1, 2024, Sernova Corp. (“Sernova” or the “Corporation”) (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH) a clinical-stage biotechnology company focused on the development of regenerativ...
Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, has filed its 2023 annual report on Form 20-F with the U.S. Securities and Exchange Commission for the year ended December 31, 2023. The annual r...
--News Direct-- Dr. Philip Toleikis to retire as of April 30, 2024 Cost savings from restructuring and strategic transformation anticipated to extend runway Board rebuild underway LONDON, Ontario; BOSTON, Massachusetts – TheNewswire - April 25, 2024 –...